Exelixis | EXEL - Gross Profit On Sales


Exelixis reported $590.86M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Amgen USD 6.89B 415M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
Bayer EUR 6.94B 1.58B Dec/2025
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Cytokinetics USD 19.2M 1.44M Mar/2026
Eisai JPY 153.41B 15.44B Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Exelixis USD 590.86M 18.68M Mar/2026
Genmab DKK 977M 13M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Incyte USD 1.17B 217.51M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
MacroGenics USD 31.11M 30.14M Dec/2025
Merck USD 10.85B 2.57B Dec/2025
Moderna USD -566M 792M Mar/2026
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sanofi EUR 8.45B 3.02B Dec/2025
Takeda JPY 688.84B 101.71B Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Xencor USD 21M 22.61M Sep/2025